



I hereby Certify that this Correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on January 14, 2008

Kathy Ashton

Name

Signature

Date of Signature

Kathy Ashton
January 14, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ansorge, et al.

Examiner: Julie Ha

Filed: June 7, 2006

Art Unit: 1654

Serial No.: 10/563,498

For: Use of DPIV and APN Inhibitors for the Treatment of Dermatological Diseases Involving the Hyperproliferation and Modified Differentiation Conditions of Fibroblasts

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the Office Action dated November 14, 2007, imposing a restriction and election of species requirement on this application. Applicants herewith elect the Group II claims (claims 5 and 13-14). Applicants further elect (Lys[Z9NO2] thiazolidide) as the species of DP IV inhibitor, actinonin as the APN inhibitor, benign fibrotic and sclerotic diseases as the species of disease, oral as the systemic application, and creams as the topical application. A preliminary amendment is forthcoming under separate cover.

Applicants request a one-month extension of time to file this response. A check for the required fee is enclosed. Any additional fees due may be charged (or any overpayment credited) to Deposit Account no. 08-2442.

01/17/2008 SSITHIB1 00000032 10563498

01 FC:1251

120.00 OP

Respectfully submitted,

By:

John D. Lopinski
John D. Lopinski, Reg. No. 50,486

HODGSON RUSS LLP
The Guaranty Building
140 Pearl Street, Suite 100
Buffalo, NY 14202-4040
Tel. 716-848-1628
Dated: January 14, 2008